Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 10/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 3/20 | 1.00 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | CDC7 | O00311 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | PRKCG | P05129 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
| ▸ | PRKACA | P17612 | 1/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | MARK3 | P27448 | 1/20 | 1.00 |
| ▸ | AKT1 | P31749 | 1/20 | 1.00 |
| ▸ | AKT2 | P31751 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-269962A SCHEMBL29365470 | 1.00 | ROCK1 (1.00) | ROCK1AURKBRPS6KA5AURKAFLT3 | |
| Gsk-269962A SCHEMBL29387396 | 1.00 | ROCK1 (1.00) | ROCK1AURKBRPS6KA5AURKAFLT3 | |
| Gsk-269962A SCHEMBL29715551 | 0.99 | ROCK1 (0.99) | ROCK1AURKBRPS6KA5AURKAFLT3 | |
| SCHEMBL4007749 | 0.95 | ROCK1 (0.90) | ROCK1AURKBRPS6KA5AURKAFLT3 | |
| SCHEMBL4002686 | 0.94 | ROCK1 (0.89) | ROCK1AURKBRPS6KA5AURKAFLT3 | |
| SCHEMBL4003195 | 0.94 | ROCK1 (0.89) | ROCK1AURKBRPS6KA5AURKAFLT3 | |
| SCHEMBL4002266 | 0.94 | ROCK1 (0.88) | ROCK1AURKBRPS6KA5AURKAFLT3 | |
| SCHEMBL4008685 | 0.93 | ROCK1 (0.87) | ROCK1AURKBRPS6KA5AURKAFLT3 | |
| SCHEMBL4004630 | 0.92 | ROCK1 (0.85) | ROCK1AURKBRPS6KA5AURKAFLT3 | |
| SCHEMBL4000210 | 0.91 | ROCK1 (0.84) | ROCK1AURKBRPS6KA5AURKAFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692329-A1 | COMPOSITION FOR INDUCING DIRECT DIFFERENTIATION OF STEM CELLS INTO CORNEAL ENDOTHELIAL CELLS AND METHOD FOR INDUCING DIRECT DIFFERENTIATION USING SAME | The Asan Foundation (KR) | 2026-02-11 | — | — | EP | claimed |
| EP-4636079-A1 | METHOD FOR INDUCING DIFFERENTIATION OF STEM CELLS INTO CORNEAL ENDOTHELIAL CELLS AND USE THEREOF | The Asan Foundation (KR) | 2025-10-22 | — | — | EP | claimed |
| US-12371664-B2 | Medium for direct differentiation of pluripotent stem cell-derived mesenchymal stem cell, method for preparing mesenchymal stem cell by using same, and mesenchymal stem cell prepared thereby | CHA BIOTECH CO., LTD. (KR) | 2025-07-29 | — | — | US | claimed |
| WO-2024210619-A1 | COMPOSITION FOR INDUCING DIRECT DIFFERENTIATION OF STEM CELLS INTO CORNEAL ENDOTHELIAL CELLS AND METHOD FOR INDUCING DIRECT DIFFERENTIATION USING SAME | 재단법인 아산사회복지재단 | 2024-10-10 | — | — | WO | claimed |
| WO-2024128696-A1 | METHOD FOR INDUCING DIFFERENTIATION OF STEM CELLS INTO CORNEAL ENDOTHELIAL CELLS AND USE THEREOF | 재단법인 아산사회복지재단 | 2024-06-20 | — | — | WO | claimed |
| US-20230391881-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING DR5-INDUCED IMMUNE EVASION BY SOLID TUMORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2023-12-07 | — | — | US | claimed |
| CN-106795487-B | Method for proliferating pancreatic progenitor cells | 武田药品工业株式会社 | 2021-11-19 | — | — | CN | claimed |
| US-20210340498-A1 | MEDIUM FOR DIRECT DIFFERENTIATION OF PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELL, METHOD FOR PREPARING MESENCHYMAL STEM CELL BY USING SAME, AND MESENCHYMAL STEM CELL PREPARED THEREBY | CHA BIOTECH CO., LTD. (KR) | 2021-11-04 | — | — | US | claimed |
| EP-3848455-A1 | MEDIUM FOR DIRECT DIFFERENTIATION OF PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELL, METHOD FOR PREPARING MESENCHYMAL STEM CELL BY USING SAME, AND MESENCHYMAL STEM CELL PREPARED THEREBY | CHA Biotech Co., Ltd. (KR) | 2021-07-14 | — | — | EP | claimed |
| US-10655105-B2 | Method for proliferation of pancreatic progenitor cells | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-05-19 | — | — | US | claimed |
| US-7547779-B2 | Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-06-16 | — | — | US | claimed |
| EP-1675552-A4 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2009-06-03 | — | — | EP | claimed |
| US-20080234261-A1 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-09-25 | — | — | US | claimed |
| EP-1675552-A2 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | claimed |
| WO-2005037197-A2 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | claimed |
| US-20260062678-A1 | CELL REPLACEMENT THERAPY FOR PULMONARY DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4692329-A1 | COMPOSITION FOR INDUCING DIRECT DIFFERENTIATION OF STEM CELLS INTO CORNEAL ENDOTHELIAL CELLS AND METHOD FOR INDUCING DIRECT DIFFERENTIATION USING SAME | The Asan Foundation (KR) | 2026-02-11 | — | — | EP | disclosed |
| EP-1675552-A2 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005037197-A2 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037197-A2 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062678-A1 | CELL REPLACEMENT THERAPY FOR PULMONARY DISEASES | WNT3A, BMP4, GSK3B | ROCK1 12/4885AURKB 1983/4885RPS6KA5 774/4885 |
| US-20230391881-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING DR5-INDUCED IMMUNE EVASION BY SOLID TUMORS | CD274, PDCD1, PDCD1LG2 | ROCK1 4/4885AURKB 416/4885RPS6KA5 1766/4885 |
| US-20080234261-A1 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors | TNK2, ROCK1, ARHGDIB | ROCK1 2/4885AURKB 101/4885RPS6KA5 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.